Physician profile
John Ip
NPI 1326049032
$79,606.86
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $27K · 2021: $14K · 2022: $19K · 2023: $1,704 · 2024: $81.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,100 · Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,100.00 |
| Food and Beverage | $685.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $78,310.01 | 2019-2024 | Aveir, Gallant, Assurity |
| Novartis Pharmaceuticals Corporation | $432.61 | 2019-2021 | |
| Medtronic, INC. | $225.66 | 2022-2024 | Micra, Azure Xt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $152.44 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $143.00 | 2019-2024 | Eliquis |
| Boston Scientific Corporation | $92.77 | 2019-2023 | Watchman Access System |
| Biotronik INC. | $58.21 | 2019-2020 | |
| Atricure, INC. | $43.58 | 2023 | |
| Sanofi-Aventis U.S. LLC | $38.16 | 2019 | |
| Elutia, INC. | $34.82 | 2020-2021 | |
| Amgen INC. | $20.71 | 2022 | |
| Astellas Pharma US INC | $18.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2019 | |
| Pfizer INC. | $13.43 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.04 | 2019-2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.